



***DEVELOPMENT OF NANODELIVERY SYSTEMS FOR
ANTI-TUBERCULOSIS DRUGS USING METAL HYDROXIDES
NANOLAYERED HOSTS***

SAIFULLAH

IB 2014 13



**DEVELOPMENT OF NANODELIVERY SYSTEMS FOR
ANTI-TUBERCULOSIS DRUGS USING METAL HYDROXIDES
NANOLAYERED HOSTS**



By

SAIFULLAH

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
Fulfillment of the Requirement for the Degree of Doctor of Philosophy**

October 2014

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia

Copyright © Universiti Putra Malaysia



DEDICATION

I dedicate my thesis to my beloved father, my paternal grandmother Mai Bhaun Bhain (Mai Amna), my beloved father Ahmed Ali Bullo, my mother, my siblings and to rest of my family.



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the Degree of Doctor of Philosophy

**DEVELOPMENT OF NANODELIVERY SYSTEMS FOR
ANTI-TUBERCULOSIS DRUGS USING METAL HYDROXIDES
NANOLAYERED HOSTS**

By

SAIFULLAH

October 2014

Chair: Prof. Mohd Zobir Bin Hussein, PhD
Faculty: Institute of Advanced Technology

Development of biocompatible and biodegradable nanodelivery systems with sustained release properties is the key research area of nanomedicine technology. Inorganic nanolayers are the promising material due to fascinating properties like ease of preparation, ability to intercalate different type of anions (inorganic, organic, biomolecules and even genes, etc.), high thermal stability, delivery of the intercalated anions in the sustained manner, high biocompatibility and easy biodegradation, etc. In this research, anti-tuberculosis (anti-TB) nanodelivery formulations were designed by intercalating anti-TB drugs into inorganic nanolayered hydroxide to be used as nanodelivery systems. *Tuberculosis* (TB) is an airborne infectious disease caused by *Mycobacterium tuberculosis* (MTB) and has been lethal to humans since centuries. Chemotherapy of TB involves multi-drug therapy, frequent dosing, and side effects of anti-TB drugs and long term treatment duration of 3-24 months. These complications are responsible for patients' noncompliance to the treatment. Drug development is very lengthy, high budget consuming and multistage process and there has been no new anti-TB drug in the market since about the last 5 decades. Research on the development of drug delivery systems is of prime importance to overcome the above scenario. Drug delivery systems (DDS) offer many advantages over the conventional chemotherapy, such as targeted delivery and protection of drugs from physico-chemical degradation, which ultimately will reduce the side effects associated with drugs. The DDS releases the drugs in a sustained manner for a longer period of time that would result in the reduction in the dosing frequency. The nano-sized DDS have the tendency to easily penetrate the bacteria and cancer cells. All of these advantages would ultimately improve the patients' compliance to the treatment.

In this research, several anti-TB nanodelivery formulations were developed by intercalating anti-TB drugs namely para amino salicylic acid (PAS) and isoniazid (INH)

into metal hydroxide nanolayers namely zinc layered (ZLH), zinc-aluminium layered double hydroxides (Zn/Al-LDHs) and magnesium-aluminium layered double hydroxides (Mg/Al-LDHs). A total of 8 nanocomposites based on the aforementioned anti-TB drugs and metal nanolayers hydroxides were prepared. The developed nanocomposites of anti-TB drugs with metal hydroxides nanolayers (inorganic nanolayers) showed higher biocompatibility with normal human lung cell lines (the most common residing place of mycobacterium tuberculosis) and with 3T3 mouse fibroblast cells (the most sensitive cells to toxicity). The release of the intercalated anti-TB drugs was sustained in human body simulated phosphate buffer (PBS) solutions of pH 7.4 and 4.8. Therapeutic efficacy of the anti-TB nanocomposites against *mycobacteria* tuberculosis was found to be much better compared to para amino salicylic acid and isoniazid in their free form. The *in vitro* study results are extremely encouraging to conduct the further study on animal models (in vivo study) and these biocompatible anti-TB nanocomposite formulations could be very useful in coping with tuberculosis effectively.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk Ijazah Doktor Falsafah

PEMBANGUNAN SISTEM PENGHANTARAN NANO BAGI UBAT ANTI-TUBERKULOSIS MENGGUNAKAN PERUMAH HYDROKSIDA LOGAM BERLAPIS NANO

By

SAIFULLAH

Oktober 2014

Chairman Prof. Mohd Zobir Bin Hussein, PhD
Faculty: Institut Teknologi Maju

Pembangunan sistem penghantaran nano yang bio-serasi dan bio-terurai dengan ciri-ciri pelepasan yang berterusan adalah merupakan tumpuan utama penyelidikan dalam teknologi perubatan-nano. Lapisan nano tak-organik adalah bahan yang menjanjikan harapan tinggi kerana sifat menariknya seperti penyediaannya yang mudah, keupayaannya untuk disisipkan dengan pelbagai jenis anion (tak-organik, organik, biomolekul dan juga gen, dll.), kestabilan haba yang tinggi, penghantaran anion tersisip secara mampan, bio-serasi yang tinggi dan mudah bio-terurai dan sifat-sifat lain lagi. Dalam kajian ini, rumusan anti-batuk kering (anti-TB) penghantar nano telah direkabentuk dengan menyisipkan ubat anti-TB ke dalam bahan tak-organik lapisan-nano hidroksida untuk digunakan sebagai sistem penghantaran nano. *Tuberculosis* (TB) adalah penyakit berjangkit bawaan udara yang disebabkan oleh *Mycobacterium tuberculosis* (MTB) yang telah membawa maut kepada manusia sejak berabad-abad lamanya. Kemoterapi TB melibatkan terapi pelbagai dadah, dos yang kerap dan kesan sampingan dari ubat-ubatan anti-TB, dan tempoh rawatan yang panjang, 3-24 bulan. Komplikasi ini bertanggungjawab terhadap ketidakpatuhan pesakit terhadap rawatan. Pembangunan ubat-ubatan baru memakan masa yang sangat panjang, bajet yang tinggi dan proses pelbagai peringkat, dan tiada ubat anti-TB baru di pasaran semenjak kira-kira 5 dekad yang lalu diperakukan. Penyelidikan terhadap pembangunan sistem penyampaian ubat adalah sangat penting untuk mengatasi senario di atas. Sistem penyampaian ubat (DDS) menawarkan banyak kelebihan berbanding dengan kemoterapi konvensional, seperti penghantaran yang dapat disasarkan dan perlindungan dadah daripada degradasi fiziko-kimia, yang akhirnya akan mengurangkan kesan sampingan yang dikaitkan dengan dadah. DDS yang mengeluarkan dadah secara berterusan untuk tempoh yang lebih lama akan menyebabkan pengurangan dalam kekerapan dos. DDS yang bersaiz nano mempunyai kecenderungan untuk lebih mudah menembusi bakteria dan sel-sel kanser. Semua kelebihan ini akhirnya akan meningkatkan pematuhan pesakit

terhadap rawatan. Dalam kajian ini, beberapa rumusan penghantar nano anti-TB dihasilkan dengan menyisipkan ubat anti-TB iaitu para-amino asid salisilik (PAS) dan isoniazid (INH) ke dalam lapisan nano hidroksida logam iaitu zink berlapis (ZLH), zink-aluminium hidroksida berlapis ganda (Zn/Al-LDH) dan magnesium-aluminium hidroksida berlapis ganda (Mg/Al-LDH). Sebanyak 8 nanokomposit berdasarkan ubat anti-TB dan lapisan nano logam hidroksida yang dinyatakan di atas telah disediakan. Nanokomposit yang dibangunkan dengan menggunakan ubat anti-TB dengan hidroksida logam berlapis nano tak-organik menunjukkan sifat serasi-bio yang lebih tinggi terhadap sel paru-paru manusia biasa (tempat yang paling biasa bagi *Mycobacterium tuberculosis*) dan dengan sel-sel 3T3 fibroblast tikus (sel-sel yang paling sensitif terhadap keracunan). Pembebasan ubat anti-TB tersisip ke dalam larutan simulasi badan manusia, fosfat penampakan (PBS) pada pH 7.4 dan 4.8 menunjukkan sifat lepasan terkawal. Keberkesanan terapeutik bagi nanokomposit anti-TB terhadap batuk kering *mycobacteria* didapati jauh lebih baik berbanding dengan para-amino asid salisilik dan isoniazid dalam bentuk bebas mereka. Keputusan kajian vitro ini amat menggalakkan, dan seterusnya kajian lanjut menggunakan model haiwan (kajian in vivo) bagi rumusan nanokomposit anti-TB yang serasi-bio ini sangat berguna untuk digunakan sebagai perawatan batuk kering yang lebih berkesan.



ACKNOWLEDGEMENTS

All praises to God Almighty who gave me strength and abilities to produce this thesis. I am very grateful to Ministry of Higher Education Commission of Malaysia for providing of fully funded PhD scholarship under Commonwealth Scholarship and Fellowship Plan (Ref: KPT.B.600-6/3, Vol. 68). I am especially thankful to my supervisor Professor Dr. Mohd Zobir B. Hussein for his kind supervision and guidance which made me able to work smoothly and for his support during the ups and downs my research work. I would also like to thank my supervisory committee Associate Professor Dr. Sharida Fakurazi, Professor Dr. Zulkernain Zainal and Dr. Nasiruddin Desa for their help and suggestions. My special thanks to Dr. Palanisamy Arulselvan for helping in conducting the cytotoxicity studies of my nanocomposites and suggestions. I would also like to acknowledge Professor Thomas J. Webster, Dr. Benjamin Geilich and North Eastern University Northeastern University, Boston 02115 for funding and help in conducting the Anti-mycobacterial assays of my samples. I would also like to thank Dr. Mohamed Ezzat El Zowalaty (Department of Environmental Health, Faculty of Public Health and Tropical Medicine, Jazan University, Jazan, Saudi Arabia) for the analyzing antimycobacterial assay data and helping me in conducting the antimicrobial assays of my samples. My special thanks to Dr. Samer Hassan Hussein Al Ali for his help, support and suggestions during my research work. I would also like to thank Professor Dr. Mohammad Iqbal Choudhary, Professor Dr. Atta ur Rehman, Professor Dr. Khalid Ahmed Khan, Professor Dr. Abdul Malik, Dr. Fayaz Ahmed Mangi, Dr. Firdus Ilyas, Dr. Shakil Ahmed, Dr. Amir Ahmed Malah, Mr. Wajid Ali, Ms Fazana from International Center for Chemical and biological Sciences, University of Karachi - 75270, Karachi Pakistan. My special thanks to my group fellows Ms Dena Dorniani, Mrs. Tumira khadiran, Mrs. Ruzanna Ibrahim, Ms Summya Megat Mohsin, Ms Julia Tan, Ms Donya Rami Mughadam and Ms Farah Naz for their moral support during my research work. I am also very thankful to my friend Mr. Musadique Ahmed Junejo, Mr. Ahmed Yar Awan, Mr. Ghiyasuddin Siddiqui, Dr. Aminu Kura, Mr. Amir Bux Baloch. I am sincerely thankful to Science officers and technicians of Institute of Advanced technology Mr. Qadri, Mrs. Sarinawani Abdul Ghani, Ms Nazira, and Mrs Norlina. My special thanks to department of Chemistry Universiti Putra Malaysia and its science and technical officers specially, Mr. Isharuddin, Mr. Zainal, Mrs Rosnani Amiruddin, Mrs Noriza Tan, Ms Norhidayu and Mr. Ismail. I am also very thankful to all of my friends from Pakistan studying University Putra Malaysia specially Mr. Zulfqar Ahmed Mahar, Gilal Arfan Ahmed, Dr. Barkatullah Qureshi, Dr. Ubedullah Kaka, Mr. Mohammad Ishaque Mastoi, Fahad Nazir Khoso, Mr. Ghulam Mujtaba Khushq, Dr. Allah Wadhayo Gandhai, Dr. Asmatullah Kakak, Dr. Mohammad Zubair, Mr. Aftab, I am very thankful for the support of my family specially my Mother, my brothers, Mr. Shafi mohammad Bullo, Mr. Asadullah Bullo, Mr. Abid Ali Bullo, Mr. Sibghatullah Bullo, Mr. Mohammad Awais Bullo, my sisters, my nephew Mr. Huzaiifa Bullo (Yaari), and rest of my family. I am specially thankful for the moral support of my Cricket Club New Pind Friends Eleven especially to my Captain Mr. Gulzar Ahmed Niazi, Mr. Dilshad Ahmed Awan, Mr. Sajid Ali Qureshi, Mr. Ameer Ali Baloch, Mr. Gul Bashah, Mr.

I certify that a Thesis Examination Committee has met on 9 October 2014 to conduct the final examination of Saifullah on his thesis entitled "Development of Nanodelivery Systems for Anti-Tuberculosis Drugs using Metal Hydroxides Nanolayered Hosts" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

Mahiran binti Basri, PhD

Professor
Faculty of Science
Universiti Putra Malaysia
(Chairman)

Md Zuki bin Abu Bakar @ Zakaria, PhD

Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Internal Examiner)

Taufiq Yap Yun Hin, PhD

Professor
Faculty of Science
Universiti Putra Malaysia
(Internal Examiner)

Hassan Ahmad, PhD

Professor
Rajshahi University
Bangladesh
(External Examiner)



NORITAH OMAR, PhD
Associate Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 23 October 2014

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy.

The members of the Supervisory Committee were as follows

Mohd. Zobir bin Hussein, PhD

Professor

Institute of Advanced Technology

Universiti Putra Malaysia

(Chairman)

Zulkarnain bin Zainal, PhD

Professor

Faculty of Science

Universiti Putra Malaysia

(Member)

Sharida Fakurazi, PhD

Associate Professor

Institute of Bioscience

Universiti Putra Malaysia

(Member)

Mohd Nasir Desa, PhD

Senior Lecturer

Faculty of Medicine

Universiti Putra Malaysia

(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean

School of Graduate Studies

Universiti Putra Malaysia

Date:

DECLARATION

Declaration by graduate student

I hereby confirm that:

- This thesis is my original work;
- Quotations, illustrations and citations have been duly referenced;
- This thesis has not been submitted previously or concurrently for any other degree at any other institution
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- Written permission must be obtained from supervisor and the office of Deputy Vice Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules,, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other material as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- There is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: _____


Date: _____


Name and Matric No.: Saifullah (GS31655)


Declaration by Members of Supervisory committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) were adhered to.

Signature: 
Name of
Chairman of
Supervisory
Committee: **PROF DR MOHD ZOBIR HUSSEIN**
MATERIALS SYNTHESIS AND CHARACTERISATION LABORATORY (MSCL)
INSTITUTE OF ADVANCED TECHNOLOGY (ITMA)
UNIVERSITI PUTRA MALAYSIA
43400 UPM SERDANG
SELANGOR MALAYSIA

Signature: 
Name of
Member of
Supervisory
Committee: **PROF. MADYA DATIN DR. HJH. SHARIDA FAKURAZI**
Ketua
Laboratori Vaksin dan Imunoterapeutik
Institut Biosains
Universiti Putra Malaysia
43400 UPM, Serdang, Selangor

Signature: 
Name of
Member of
Supervisory
Committee: **PROF. DR. ZULKARNAIN B. ZAINAL**
PROFESOR
JABATAN KIMIA
FAKULTI SAINS
UNIVERSITI PUTRA MALAYSIA
43400 UPM SERDANG
SELANGOR DARUL EHSAN.


Signature: 
Name of
Member of
Supervisory
Committee: **PROF MADYA DR MOHD NASIR MOHD DESA**
BSc(Arizona), MMedSc(Malaya), PhD(Malaya)
Jabatan Sains Bioperubatan
Fakulti Perubatan & Sains Kesihatan
Universiti Putra Malaysia
43400 UPM Serdang,
Selangor D.E.

TABLE OF CONTENTS

ABSTRACT	Page
ABSTRAK	i
ACKNOWLEDGEMENTS	iii
APPROVAL	v
DECLARATION	vi
LIST OF TABLES	viii
LIST OF FIGURES	xviii
	xx

CHAPTER

1	INTRODUCTION	1
	1.1 Background of study	1
	1.2 Problem statement	1
	1.3 Objectives	2
	1.4 Significance of study	2
	1.5 References	3
2	LITERATURE REVIEW (Part-A)	4
	2.1 Controlled-release approaches towards the chemotherapy of tuberculosis	4
	2.2 Copyright Permission from Dove Press	4
	2.3 Abstract	5
	2.4 Introduction	6
	2.5 Types of tuberculosis	6
	2.5.1 Drug susceptible tuberculosis	6
	2.5.2 Multidrug Resistant tuberculosis	6
	2.5.3 Extensively resistant tuberculosis	7
	2.6 Para amino salicylic acid	8
	2.7 Isonicotinic acid hydrazine (Isoniazid)	8
	2.8 Macrophages and survival mechanism of tuberculosis bacteria in macrophages	9
	2.8.1 Macrophages	9
	2.8.2 Inhibition of phagosome lysosome fusion	11
	2.8.3 Inhibition of phagosomal acidification	11
	2.8.4 Protection against oxidative radicals	11
	2.8.5 Tryptophan aspartate-containing coat on the phagosome wall	11
	2.9 Responding to tuberculosis intelligently with limited chemotherapy options	12

2.10	Drug Delivery Systems for chemotherapy tuberculosis	13
2.11	Drug Delivery Systems for pulmonary tuberculosis chemotherapy	15
2.12	Drug delivery systems for the targeted and slow delivery of anti-TB drugs	16
2.12.1	Inhalable large porous particles (LPPs) of capreomycin	16
2.12.2	Inhalable rifampin-containing mannitol microparticles	17
2.12.3	Inhalable microparticles of polylactic acid	18
2.12.4	Tuneable systems for the controlled release of drugs into the lungs	19
2.12.5	Glucan particles (GPs) as a targeted delivery system to macrophages	20
2.12.6	Plant proteins as drug delivery system	21
2.12.7	Gelatin nano-vehicles	22
2.12.8	Chitosan-montmorillonite (MMT) hydrogel	23
2.12.9	Nanocomposite hydrogels of polyvinyl alcohol: sepiolite	24
2.12.10	Bioceramic systems for osteoarticular tuberculosis	25
2.12.11	Advantages of drug delivery system in tuberculosis chemotherapy	26
2.13	Conclusion	28
2.14	Acknowledgments	28
2.15	Disclosure	28
2.16	References	29
	LITERATURE REVIEW (PART-B)	34
2.17	Inorganic nanolayers structure, preparation and Biomedical applications	34
2.18	Abstract	35
2.19	Introduction	37
2.20	Structure of the inorganic metal nanolayers	37
2.20.1	Structure of brucite	37
2.20.2	Structure of layered double hydroxides	38
2.20.3	Structure of layered hydroxides	39
2.21	Miscellaneous applications of layered Double hydroxides	40

2.22	Drug delivery applications of layered double hydroxides	41
2.22.1	Layered double hydroxides in anticancer formulations	41
2.22.2	Layered double hydroxides in antimicrobial formulations	44
2.22.3	Layered double hydroxides as antimicrobial biomaterial	45
2.22.4	Layered double hydroxides in gene delivery	46
2.22.5	Layered double hydroxides as gene protective biomaterial	48
2.23	Sustained Release from inorganic nanolayers	51
2.24	Zeta potential	53
2.25	Cellular Uptake of layered double hydroxides	53
2.25.1	Cellular uptake mechanism	53
2.25.2	Mechanism of leaving the cell	54
2.26	Cytotoxicity assay	55
2.27	Biocompatibility of layered double hydroxides	56
2.28	Conclusive discussion	60
2.29	References	63
3	SUSTAINED RELEASE FORMULATION OF AN ANTI-TUBERCULOSIS DRUG BASED ON PARA AMINO-SALICYLIC ACID-ZINC LAYERED HYDROXIDE NANOCOMPOSITE	76
3.1	Copyright permission from Biomed Central Springer	76
3.2	Abstract	77
3.3	Introduction	78
3.4	Materials and methods	80
3.4.1	Materials	80
3.4.2	Preparation	80
3.4.3	Controlled release study	80
3.4.4	Cell culture	80
3.4.5	Methyl tetrazolium (MTT) assay	81
3.4.6	Characterization	81
3.4.7	Controlled release of P.aminosalicylic acid	81
3.4.8	Cell culture	81
3.4.9	MTT assay for cytotoxic study	82
3.4.10	Characterization	82
3.5	Results and Discussion	82
3.5.1	Powder X-ray diffraction	82
3.5.2	Spatial orientation of intercalated para amino salicylic acid	84

3.5.3	Infrared spectroscopy	84
3.5.4	Elemental analysis	86
3.5.5	Thermal analysis	87
3.5.6	Surface properties	88
3.5.7	In vitro release study	90
3.5.8	Kinetics study of the <i>in vitro</i> release	91
3.5.9	Cytotoxic study	93
3.6	Conclusion	95
3.7	Competing interests	96
3.8	Acknowledgements	96
3.9	References	97
4	DEVELOPMENT OF A HIGHLY BIOCOMPATIBLE ANTI-TUBERCULOSIS NANODELIVERY FORMULATION BASED ON PARA-AMINO SALICYLIC ACID ZINC LAYERED HYDROXIDE NANOCOMPOSITE	100
4.1	Copyright permission from Hindawi	100
4.2	Abstract	102
4.3	Introduction	103
4.4	Materials and methods	104
4.4.1	Preparation of zinc layer hydroxides	104
4.4.2	Preparation Para aminosalicic acid-zinc layered hydroxide nanocomposite	104
4.4.3	Material characterization	105
4.4.4	Controlled-release study	105
4.4.5	Bacterial studies	106
4.5	Results and discussion	108
4.5.1	X-ray Diffraction (XRD) analysis	108
4.5.2	Spatial Orientation of para aminosalicic acid	109
4.5.3	Infrared spectroscopy	110
4.5.4	High Performance liquid chromatographic analysis	112
4.5.5	Elemental analysis	112
4.5.6	Thermogravimetric analysis	113
4.5.7	Surface morphology	114
4.5.8	In vitro release	116
4.5.9	Kinetics study of <i>in vitro</i> release	116
4.5.10	Particle size analysis	118
4.5.11	Antimycobacterial and antimicrobial assays	119
4.5.12	Cytotoxic study	122
4.6	Conclusion	125
4.7	Acknowledgement	125
4.8	Funding	125
4.9	References	126

5	ANTI-TUBERCULOSIS NANODELIVERY SYSTEM WITH CONTROLLED-RELEASE PROPERTIES BASED ON PARA-AMINOSALICYLATE – ZINC ALUMINIUM – LDHS NANOCOMPOSITES	130
	5.1 Copyright Permission from Dove Pres	130
	5.2 Abstract	131
	5.3 Introduction	132
	5.4 Materials and methods	133
	5.4.1 Preparation of zinc aluminum-layered double hydroxides	133
	5.4.2 Preparation of para aminosalicylic acid –zinc Aluminium layered double hydroxides nanocomposite by method.	133
	5.4.3 Preparation of aminosalicylic acid –zinc aluminum layered double hydroxides nanocomposite by ion exchange method	134
	5.4.4 Controlled-release study	134
	5.4.5 Cell culture	134
	5.4.6 Cell viability assays	135
	5.4.7 Characterization	135
	5.5 Results and discussion	135
	5.5.1 Powder X-ray diffraction	135
	5.5.2 Orientation of para amino salicylic acid interlayers of zinc aluminum layered double hydroxides	137
	5.5.3 Infrared spectroscopy	138
	5.5.4 Elemental analysis	140
	5.5.5 Thermal analysis	140
	5.5.6 Surface morphology	141
	5.5.7 In vitro release study	142
	5.5.8 Kinetics study of in vitro release	143
	5.5.9 Cytotoxicity study	145
	5.6 Conclusion	149
	5.7 Acknowledgments	149
	5.8 References	150
6	ANTIMYCOBACTERIAL, ANTIMICROBIAL AND BIOCOMPATIBILITY PROPERTIES OF PARA AMINOSALICYLIC ACID WITH ZINC LAYERED HYDROXIDE AND ZINC ALUMINUM LAYERED DOUBLE HYDROXIDE NANOCOMPOSITES	153
	6.1 Copyright Permission from Dove Press	153
	6.2 Abstract	154
	6.3 Introduction	155
	6.4 Material and methods	157
	6.4.1 Materials	157

6.4.2	Preparation of para aminosalicylic acid –zinc aluminum-layered double hydroxides and para aminosalicylic –zinc layered hydroxides	157
6.4.3	Characterization	157
6.4.4	High-Performance Liquid Chromatography (HPLC) Analysis	157
6.4.5	Anti-mycobacterial antimicrobial susceptibility Test	158
6.4.6	Non-mycobacterium antimicrobial susceptibility Test	158
6.4.7	Statistical analysis	159
6.4.8	Cell culture	159
6.5	Results and discussion	160
6.5.1	Powder X-ray Diffraction (XRD)	160
6.5.2	High-Performance Liquid Chromatography (HPLC) Analysis	161
6.5.3	Anti-tuberculosis and antimicrobial activity	162
6.5.4	Cytotoxicity study	164
6.6	Conclusion	165
6.7	Acknowledgements	166
6.8	Funding	166
6.9	References	167
7	DEVELOPMENT OF A BIOCOMPATIBLE NANODELIVERY SYSTEM FOR TUBERCULOSIS DRUGS BASED ON A ISONIAZID-MG/AL LAYERED DOUBLE HYDROXIDES	170
7.1	Copyright Permission from Dove Press	170
7.2	Abstract	171
7.3	Introduction	172
7.4	Materials and Methods	173
7.4.1	Preparation of isoniazid-magnesiumaluminum layered double hydroxides by ion exchange method	173
7.4.2	Preparation of isoniazid-magnesiumaluminum layered double hydroxides by co-precipitation method	173
7.4.3	Material Characterization	174
7.4.4	Sustained Release Study	174
7.4.5	Mycobacterial Antimicrobial Susceptibility Testing Using MGIT	174
7.4.6	Non-Mycobacterium Antimicrobial Susceptibility Testing	175
7.4.7	Statistical analysis	175
7.4.8	Cell Culture	175

7.4.9	In vitro Cell viability Assays	175
7.5	Results and Discussion	176
7.5.1	X-ray Diffraction (XRD) Analysis	176
7.5.2	Spatial Orientation of isoniazid	177
7.5.3	Fourier Transform Infrared Spectroscopy	178
7.5.4	Elemental Analysis	180
7.5.5	Thermal Analysis	181
7.5.6	In vitro release of isoniazid	182
7.5.7	Release Kinetics of isoniazid	183
7.5.8	Surface Morphology	185
7.5.9	Antimycobacterial and Antimicrobial Assays	187
7.5.10	Cytotoxicity Study	189
7.6	Conclusion	193
7.7	Abbreviations	193
7.8	Acknowledgements	193
7.9	References	193
8	ANTI-TUBERCULOSIS NANODELIVERY FORMULATION WITH HIGH EFFICACY AND BIOCOMPATIBILITY BASED ON ISONIAZID- Zn/AL LAYERED DOUBLE HYDROXIDE NANOCOMPOSITES	194
8.1	Abstract	198
8.2	Introduction	199
8.3	Materials and Methods	200
8.3.1	Chemicals	200
8.3.2	Cell culture	201
8.3.3	Characterization	201
8.3.4	Preparation of the isoniazid-zinc aluminum layered double hydroxides nanocomposite using coprecipitation	201 202
8.3.5	Preparation of the isoniazid- zinc aluminum layered double hydroxides nanocomposite using ion exchange	202
8.3.6	Sustained-release Study	202
8.3.7	Antimicrobial-susceptibility tests	202
8.3.8	Growth-inhibition kinetics	203
8.3.9	In vitro assay for cell viability	204
8.4	Results and Discussion	204
8.4.1	Powder X-ray diffraction	204
8.4.2	Spatial orientation of isoniazid between the interlayer galleries of the zinc aluminum layered double hydroxides	205
8.4.3	Fourier transform infrared spectroscopy	206
8.4.4	Elemental analysis	208

8.4.5	Quantification of INH by HPLC analysis	209
8.5.6	Thermal Study	210
8.4.7	In vitro release study	212
8.4.8	Kinetic study of <i>in vitro</i> release	213
8.4.9	Surface morphology	215
8.4.10	Antituberculosis and antimicrobial activity	216
8.4.11	Cytotoxicity study on human normal lung normal lung cells MRC-5 and 3T3 fibroblast cells	219
8.5	Conclusion	222
8.6	Acknowledgments	223
8.7	Funding	223
8.8	References	224
9	CONCLUSION AND RECOMMENDATIONS	228
9.1	Selection of best nanodelivery system from the designed carriers	230
9.2	Recommendations	231
APPENDICES		232
Appendix A		232
Appendix B		233
Appendix C		234
Appendix D		235
Appendix E		236
BIODATA OF STUDENT		237
LIST OF PUBLICATIONS		238

LIST OF TABLES

Table		Page
2.1	Structures of first-line antituberculosis drugs	7
2.2	Side effects of first-line antituberculosis drugs	14
2.3	Side effects of second-line antituberculosis drugs	15
2.4	Advantages and disadvantages different drug-delivery systems	27
2.5	Biomedical applications of inorganic nanolayers	49
2.6	In vitro biocompatibility of layered double hydroxides	58
2.7	In vivo biocompatibility of LDHs	60
3.1	FTIR assignments for para amino salicylic acid and PAS-nanocomposite	86
3.2	Elemental analysis of free para amino salicylic acid and its nanocomposite	87
3.3	Correlation coefficient (R^2), and rate constants (k)	93
4.1	FTIR functional groups absorption bands of free PAS and its PAS-ZLH	112
4.2	Elemental analysis of organic and inorganic elements	113
4.3	Rate constant (k) and correlation coefficient R^2	117
5.1	Assignments of FTIR absorption bands of free PAS, PAS-D and PAS-I nanocomposites	139
5.2	Chemical compositions of PAS, PAS-D and PAS-I nanocomposites	140
5.3	Correlation coefficient (R^2), and rate constants (k)	145
6.1	Percentage loading of PAS in nanocomposites determined by HPLC analysis	162
7.1	Vibrational wavenumbers of functional groups of INH and its nanocomposites	180
7.2	Elemental composition of free isoniazid and nanocomposite A and nanocomposite B	181
7.3	Correlation coefficient (R^2), and rate constants (k) for kinetic study	185
8.1	FTIR Vibrational wavenumbers of the functional groups	208
8.2	Elemental composition of isoniazid (INH), nanocomposites	209
8.3	Correlation coefficient (R^2) and rate constants (k)	214

8.4	Percentage inhibition of the INH nanocomposites on microorganisms growth	217
9.1	Summary of Research	229



LIST OF FIGURES

Figure	Page
2.1 Structure of para aminosalicylic acid	8
2.2 Structure of isonicotinic acid hydrazine	9
2.3 Detailed structure of a macrophage showing a typical process of phagocytosis	10
2.4 Important factors of the survival mechanisms Mycobacterium tuberculosis	12
2.5 Structure of capreomycin	17
2.6 Scanning electron micrograph of spray-dried capreomycin dry powder	18
2.7 Schematic representation of rifampin (Rif) loaded into Glucan particles	21
2.8 Different forms of Zein	22
2.9 Application of inorganic nanolayers schematic representation	36
2.10 Schematic representation of the brucite structure	38
2.11 Schematic representation of the structure of LDH	39
2.12 Structures of zinc hydroxide nitrate side view (a) and top view (b)	40
2.13 Confocal microscopic images of intracellular localization in NSC 34 cells	47
2.14 Release profiles of levodopa from the nanocomposite at pH 7.4 and pH 4.8	52
2.15 Endocytosis uptake mechanisms	54
2.16 Molecular structure of trypan blue	56
3.1 Powder X-ray diffraction patterns for Zinc oxide, Free PAS and PAS-zinc layered hydroxides nanocomposite	83
3.2 Three dimensional structure of PAS and its spatial orientation between the layers	84
3.3 FTIR spectra of free para amino salicylic acid (A) and PAS	85
3.4 TGA-DTG thermograms of para amino salicylic acid (A) and PAS-zinc layered hydroxide nanocomposites	88
3.5 Scanning electron micrographs of ZnO and PAS-ZLH nanocomposite	89
3.6 Surface area analysis isotherm	90
3.7 In vitro release of PAS from PAS-ZLH nanocomposite	91
3.8 Kinetic Model fitting of in vitro release	92
3.9 Cytotoxic effect of PAS, ZnO and PAS-ZLH on fibroblast cells 3T3 for 24 hours	94
3.10 Cytotoxic effect of PAS, ZnO & PAS-ZLH on fibroblast cells -3T3 for 48 hours.	94
3.11 Cytotoxic effect of PAS, ZnO & PAS-ZLH on fibroblast cells -3T3 for 72 hours.	95

4.1	X-ray Diffraction pattern of zinc layered hydroxide (ZLH) and PAS-Zinc layered hydroxide nanocomposite	109
4.2	Spatial orientation of PAS in interlayers of ZLH (nanocomposite A)	110
4.3	Infrared spectrum of para aminosalicylic acid and its nanocomposite	111
4.4	Thermogravimetric analysis–thermograms of PAS-ZLH	114
4.5	FESEM micrographs of ZLH and PAS-ZLH (nanocomposite A)	115
4.6	In vitro release of PAS from PAS-ZLH (nanocomposite A)	116
4.7	Kinetic Fitting data for PAS in vitro release from PAS-ZLH	118
4.8	Hydrodynamic size of the PAS-ZLH nanocomposite	119
4.9	Minimum inhibitory concentrations of PAS-ZLH	120
4.10	Effect of PAS-ZLH (nanocomposite A) on the inhibition of microbial growth using plate colony counting method at two concentrations	121
4.11	PAS-ZLH (Nanocomposite A) against mouse fibroblast cells 3T3	122
4.12	Cytotoxicity of samples on Lung Cells MRC-5 of PAS-ZLH (nanocomposite A) and the carrier ZLH after 24 hours incubation,	123
4.13	Human normal Lung Cells MRC-5 treated with PAS-ZLH (nanocomposite A) and the carrier ZLH for 48 hours	124
4.14	Human normal Lung Cells MRC-5 treated with PAS-ZLH (nanocomposite A) and the carrier ZLH for 72 hours	124
5.1	X-ray diffraction patterns of PAS-D (A), PAS-I (B) and free PAS	136
5.2	Three-dimensional structure of PASA (A) and molecular structural models	137
5.3	FTIR Spectra of (A) (PAS), (B) PAS-D, and (C) PAS-I	139
5.4	TGA-DTG thermograms of PAS (A), PAS-D (B), and PAS-I (C)	141
5.5	Scanning Electron micrographs of PAS-Zn/Al-LDHs	142
5.6	Release profiles of PAS from PAS-Zn/Al-LDHs	143
5.7	Fitting the data of PAS release from PAS-Zn/Al-LDHs	144
5.8	Cytotoxicity of samples on 3T3 fibroblast cells treated for 24 Hours	146
5.9	Cytotoxicity of samples on 3T3 fibroblast cells treated for 48 Hours	146
5.10	Cytotoxicity of samples on 3T3 fibroblast cells treated for 72 Hours	147
5.11	Cytotoxicity of samples on human lung fibroblast MRC-5 cells treated for 24 hours	147
5.12	Human lung fibroblast MRC-5 lung cells treated for 48 hours	148
5.13	Cytotoxicity of samples on human lung fibroblast MRC-5 cells treated for 72 hours	148
6.1	X-ray diffraction patterns of nanocomposite	160

6.2	HPLC Calibration curves of para aminosalicylic acid	161
6.3	Minimum inhibitory concentrations PAS nanocomposites	162
6.4	Effect of PAS nanocomposites (1mg) on the inhibition of microbial growth	163
6.5	Effect of PAS nanocomposites (2mg) on the inhibition of microbial growth	163
6.6	Cytotoxicity of samples on human lung fibroblasts MRC-5	165
7.1	Powder X-ray Diffraction patterns of isoniazid and nanocomposites	177
7.2	Molecular size of isoniazid and its spatial orientation the interlayer	178
7.3	FTIR Spectra of isoniazid and its Mg/Al-LDHs nanocomposites	179
7.4	Thermograms for isoniazid and its nanocomposites with Mg/Al-LDHs	182
7.5	In vitro release of isoniazid from nanocomposites with Mg/Al-LDHs	183
7.6	Pseudo second order kinetics of the isoniazid release from Mg/Al-LDHs	184
7.7	FESEM micrographs of isoniazid and its nanocomposites with Mg/Al-LDHs	186
7.8	Minimum inhibitory concentration of INH nanocomposites	187
7.9	Effect of INH nanocomposites (1mg) on the inhibition of microbial growth	188
7.10	Effect of INH nanocomposites (2mg) on the inhibition of microbial growth	188
7.11	Viability of fibroblast cells-3T3 when treated for 24 hours	190
7.12	Viability of fibroblast cells-3T3 when treated for 48 hours	190
7.13	Viability of fibroblast cells-3T3 when treated for 72 hours	191
7.14	Viability of human lung fibroblast MRC-5 cells when treated for 24 hours	191
7.15	Cytotoxicity of samples on human lung fibroblast MRC-5 cells treated for 48 hours	192
7.16	Cytotoxicity of samples on human lung fibroblast MRC-5 cells treated for 72 hours	192
8.1	XRD pattern for the isoniazid (INH) and its Zn/Al-LDHs nanocomposites	205
8.2	Spatial orientation of isoniazid between the inorganic interlayers	206

8.3	FTIR Spectra of isoniazid (INH) and nanocomposites A and B	207
8.4	Calibration curve obtained with standard concentrations of isoniazid	210
8.5	Thermogravimetric analysis of INH and its Zn/Al-LDHs nanocomposites	211
8.6	Release of isoniazid from its Zn/Al-LDHs nanocomposites	213
8.7	Pseudo-second-order kinetics of the isoniazid release from INH-Zn/Al-LDHs	215
8.8	FESEM micrographs for the surface morphology of INH-Zn/Al-LDHs	216
8.9	The MICs of INH, Zn/Al-LDHs and the nanocomposites A and B against TB	217
8.10	Antimicrobial activity using 1mg of INH and its Zn/Al-LDHs Zn/Al-LDHs nanocomposites	218
8.11	Antimicrobial activity using 2 mg INH and its Zn/Al-LDHs nanocomposites	218
8.12	Cytotoxicity of samples on 3T3 fibroblast cells treated for 24 hours	219
8.13	Viability of fibroblast cells when treated for 24 hours against INH-Zn/Al-LDHs	220
8.14	Viability of fibroblast cells when treated for 48 hours against INH-Zn/Al-LDHs	220
8.15	Viability of fibroblast cells when treated for 72 hours against INH-Zn/Al-LDHs	221
8.16	Viability of human lung fibroblast MRC-5 cells when treated for 24 hours	221
8.17	Viability of human lung cells treated for 48 and 72 hours	222

CHAPTER 1

INTRODUCTION

1.1 Background of study

Inorganic nanolayers are the two dimensional nanomaterial whose structure is made up of infinite layers and the thickness of their layers in nanoscale range. Layered double hydroxides (LDHs) and layered hydroxide salts (LHS) are the types of inorganic nanolayered material having thickness in nanoscaled range (1-100nm)[1] . Drug delivery, gene delivery, biosensing science and bioimaging technology are the key tools of the modern-day biomedical sciences. Different materials are used for the application of the above mentioned biomedical tools but there are certain issues related to different materials such as cytotoxicity, lack of biodegradation and different types of material is used for individual application [2]. Inorganic nanolayers have many advantages for biomedical applications. It has been proven to be very high in vitro and in vivo biocompatibility, biodegradable, tendency to release the intercalated drugs in a sustained manner and is single material can be applied as drug delivery, gene delivery, biosensing and in bioimaging sciences [3-6]. Inorganic metal nanolayered hydroxides have been widely applied for the delivery of various pharmaceutical drugs and have found to be promising in improving the bioavailability of drugs, better biocompatibility and therapeutic efficacy [6-8].

1.2 Problem statement

Tuberculosis (TB) is an airborne infectious disease caused by the bacterium *Mycobacterium tuberculosis* (MTB). Tuberculosis can be classified in two types based of the infections, (1) Pulmonary tuberculosis, when MTB infect the lungs and (2) Extra pulmonary tuberculosis when MTB infect other organs of humans except lungs such as liver, spleen, kidneys, tonsils, intestine, brain and bones etc [9]. Tuberculosis has been lethal to humans for centuries till today and according the most recent global TB report (2013) by world health organization (WHO) there are about 8.6 million people were new cases of TB and approximately 1.3 million human died from the disease in the year 2012 [10]. Chemotherapy of TB is complicated by number of factors such as multidrug prescription, frequent dosage, adverse side effects anti-TB drugs and long treatment duration (6-24months). All of these factors result in the patients' noncompliance to the chemotherapy of tuberculosis and patients' noncompliance is the most common cause for the treatment failure. And unfortunately no new anti-TB drug has been introduced in the market in last 5 decades as the drug development is very lengthy and budget consuming process [10]. In this scenario when there has been no new anti-TB drug introduced in the market. We need to make better utilization of currently available anti-TB drugs. We can do this by reducing the adverse effect of the drugs, improving the

bioavailability of drugs and by reducing the concentration of dosages and by decreasing the dosing frequency of drugs. We can achieve all these important properties with biocompatible and biodegradable drug delivery systems having sustained release properties. Inorganic nanolayered metal hydroxides have all of these characteristics to be applied as drug delivery systems for anti-TB drugs.

1.3 Objectives

Following are the objective of the study

1. To prepare anti-TB nanodelivery formulation based anti-TB drugs Isoniazid and Para aminosalicylic acid using metal layered hydroxides host (Zn/Al-LDHs and Mg/Al-LDHs). To characterize the designed anti-TB nanodelivery systems using different analytical techniques (XRD, FT-IR, HPLC, CHNS, UV/Vis and FESEM)
2. To determine the *in vitro* release of these anti-TB drugs in human body simulated PBS solution from the nanolayered host.
3. To determine their *in vitro* cytotoxicity on human normal lung cell MRC-5 and 3T3 fibroblast cells.
4. To determine their therapeutic effect against mycobacteria tuberculosis and other Gram positive and Gram negative bacteria.

1.4 Significance of study

This study was carried out to design sustained release formulations of anti-TB drugs with biocompatible capabilities for the anti-tuberculosis drugs namely para aminosalicylic acid and isoniazid with inorganic nanolayers. The sustained release nanocomposites formulations have the potential to enhance the bioavailability of drug for longer period of time by sustained release of the drugs, thereby would reduce the dosing frequency of the drugs, protect the drug from physico-chemical degradations inside the body, and reduce the adverse effects to the drugs. All of these advantages would improve the patients' compliance to the treatment of tuberculosis and would make the chemotherapy of tuberculosis patients' friendly.

1.5 References

1. Rives, V., Layered Double Hydroxides: Present and Future Nova Science Pub Inc. 2001.
2. Wang, R. Mikoryak, C. Li, S. Bushdiecker, D. Musselman, I. H. Pantano, P. Draper, R. K., Cytotoxicity Screening of Single-Walled Carbon Nanotubes: Detection and Removal of Cytotoxic Contaminants from Carboxylated Carbon Nanotubes. *Molecular Pharmaceutics* 2011, 8 (4), 1351-1361.
3. Zhang, H. Ouyang, D. Murthy, V. Wong, Y. Xu, Z. Smith, S. C., Hydrotalcite Intercalated siRNA: Computational Characterization of the Interlayer Environment. *Pharmaceutics* 2012, 4 (2), 296-313;
4. Wang, Q. O'Hare, D., Recent advances in the synthesis and application of layered double hydroxide (LDH) nanosheets. *Chemical reviews* 2012, 112 (7), 4124-55.
5. Wang, J. Zhu, R. Gao, B. Wu, B. Li, K. Sun, X. Liu, H. Wang, S., The enhanced immune response of hepatitis B virus DNA vaccine using SiO₂@LDH nanoparticles as an adjuvant. *Biomaterials* 2014, 35 (1), 466-78.
6. Rives, V. del Arco, M. Martín, C., Intercalation of drugs in layered double hydroxides and their controlled release: A review. *Applied Clay Science* 2014, 88–89 (0), 239-269.
7. Bashi, A. M. Hussein, M. Z. Zainal, Z. Tichit, D., Synthesis and controlled release properties of 2,4-dichlorophenoxy acetate–zinc layered hydroxide nanohybrid. *Journal of Solid State Chemistry* 2013, 203 (0), 19-24.
8. Rives, V. del Arco, M. Martín, C., Layered double hydroxides as drug carriers and for controlled release of non-steroidal antiinflammatory drugs (NSAIDs): A review. *Journal of Controlled Release* 2013, 169 (1–2), 28-39.9.
9. S. J. Antony, V. H., J. D. Christie, H. G. Adams, and R. L. Rumley, Clinical differences between pulmonary and extrapulmonary tuberculosis: a 5-year retrospective study. *J Natl Med Assoc.* 1995, 87 (3), 187.
10. World Health Organization, W. H., Global tuberculosis report 2013. WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. 2013.

8.8 References

1. UNAIDS, W. H. O. G. T. P. a. Policy statement on preventive therapy against tuberculosis in people living with HIV; WHO/TB/98.255, UNAIDS/98.34; 1998; p 20.
2. Sumartojo, E., When tuberculosis treatment fails. A social behavioral account of patient adherence. *The American review of respiratory disease* 1993, 147 (5), 1311-20.
3. Cuneo, W. D. Snider, D. E., Jr., Enhancing patient compliance with tuberculosis therapy. *Clinics in chest medicine* 1989, 10 (3), 375-80.
4. WHO, W. H. o., Guidelines for the programmatic management of drug-resistant tuberculosis. 2011, 44.
5. Hasan, S. Al Ali, H. Al-Qubaisi, M. Zobir Hussein, M. Ismail, M. Zainal, Z. Nazrul Hakim, M., Controlled-release formulation of antihistamine based on cetirizine zinc-layered hydroxide nanocomposites and its effect on histamine release from basophilic leukemia (RBL-2H3) cells. *International journal of nanomedicine* 2012, 7, 3351-63.
6. Sharma, S. K. Mohan, A., Extrapulmonary tuberculosis. *The Indian journal of medical research* 2004, 120 (4), 316-53.
7. World Health Organization, Global tuberculosis report 2013; WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland., 2013.
8. Agarwal, S. Gupta, M. Choudhury, B., Solvent free biocatalytic synthesis of isoniazid from isonicotinamide using whole cell of *Bacillus smithii* strain IITR6b2. *Journal of Molecular Catalysis B: Enzymatic* 2013, 97 (0), 67-73.
9. Campos-Franco, J. Gonzalez-Quintela, A. Alende-Sixto, M. R., Isoniazid-induced hyperacute liver failure in a young patient receiving carbamazepine. *European journal of internal medicine* 2004, 15 (6), 396-397.
10. Vidrio, H. Medina, M. Fernández, G. Lorenzana-Jiménez, M. Campos, A. E., Enhancement of hydralazine hypotension by low doses of isoniazid: Possible role of semicarbazide-sensitive amine oxidase inhibition. *General Pharmacology: The Vascular System* 2000, 35 (4), 195-204.
11. Tafazoli, S. Mashregi, M. O'Brien, P. J., Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. *Toxicology and applied pharmacology* 2008, 229 (1), 94-101.
12. Van Hest, R. Baars, H. Kik, S. van Gerven, P. Trompenaars, M. C. Kalisvaart, N. Keizer, S. Borgdorff, M. Mensen, M. Cobelens, F., Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2004, 39 (4), 488-96.
13. Bermudez, L. E. Goodman, J., *Mycobacterium tuberculosis* invades and replicates within type II alveolar cells. *Infection and immunity* 1996, 64 (4), 1400-6.
14. Flynn, J. L. Chan, J., Immune evasion by *Mycobacterium tuberculosis*: living with the enemy. *Current opinion in immunology* 2003, 15 (4), 450-5.
15. Gupta, A. Kaul, A. Tsolaki, A. G. Kishore, U. Bhakta, S., *Mycobacterium tuberculosis*: immune evasion, latency and reactivation. *Immunobiology* 2012, 217 (3), 363-74.

16. Clemens, D. L. Lee, B. Y. Xue, M. Thomas, C. R. Meng, H. Ferris, D. Nel, A. E. Zink, J. I. Horwitz, M. A., Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. *Antimicrobial agents and chemotherapy* 2012, 56 (5), 2535-45.
17. Saifullah, B. Hussein, M. Z. Hussein-Al-Ali, S. H. Arulselvan, P. Fakurazi, S., Sustained release formulation of an anti-tuberculosis drug based on para-amino salicylic acid-zinc layered hydroxide nanocomposite. *Chemistry Central journal* 2013, 7 (1), 72.
18. Chen, H. Wang, L. Yeh, J. Wu, X. Cao, Z. Wang, Y. A. Zhang, M. Yang, L. Mao, H., Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. *Biomaterials* 2010, 31 (20), 5397-407.
19. He, Q. Zhang, Z. Gao, F. Li, Y. Shi, J., In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. *Small (Weinheim an der Bergstrasse, Germany)* 2011, 7 (2), 271-80.
20. Anisimova, Y. V. Gelperina, S. I. Peloquin, C. A. Heifets, L. B., Nanoparticles as Antituberculosis Drugs Carriers: Effect on Activity Against Mycobacterium tuberculosis in Human Monocyte-Derived Macrophages. *Journal of Nanoparticle Research* 2000, 2 (2), 165-171.
21. Lee, J. E. Lee, N. Kim, H. Kim, J. Choi, S. H. Kim, J. H. Kim, T. Song, I. C. Park, S. P. Moon, W. K. Hyeon, T., Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. *Journal of the American Chemical Society* 2010, 132 (2), 552-7.
22. Lam, K. H. Schakenraad, J. M. Esselbrugge, H. Feijen, J. Nieuwenhuis, P., The effect of phagocytosis of poly(L-lactic acid) fragments on cellular morphology and viability. *Journal of biomedical materials research* 1993, 27 (12), 1569-77.
23. Marques, A. P. Reis, R. L. Hunt, J. A., Cytokine secretion from mononuclear cells cultured in vitro with starch-based polymers and poly-L-lactide. *Journal of biomedical materials research. Part A* 2004, 71 (3), 419-29.
24. Ramappa, V. Aithal, G. P., Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. *Journal of Clinical and Experimental Hepatology* 2013, 3 (1), 37-49.
25. Wang, Q. O'Hare, D., Recent advances in the synthesis and application of layered double hydroxide (LDH) nanosheets. *Chemical reviews* 2012, 112 (7), 4124-55.
26. Del Hoyo, C., Layered double hydroxides and human health: An overview. *Applied Clay Science* 2007, 36 (1-3), 103-121.
27. Cavani, F. Trifirò, F. Vaccari, A., Hydrotalcite-type anionic clays: Preparation, properties and applications. *Catalysis Today* 1991, 11 (2), 173-301.
28. Saifullah, B. Hussein, M. Z. Hussein-Al-Ali, S. H. Arulselvan, P. Fakurazi, S., Antituberculosis nanodelivery system with controlled-release properties based on para-amino salicylate-zinc aluminum-layered double-hydroxide nanocomposites. *Drug design, development and therapy* 2013, 7, 1365-75.

29. V. Rives, V., Angelo, Layered double hydroxides: present and future: , Nova Science Publishers, Inc., New York, 2001, IX+439 pp., ISBN 1-59033-060-9. Applied Clay Science 2002, 22 (1–2), 75-76.
30. Rives, V. del Arco, M. Martín, C., Intercalation of drugs in layered double hydroxides and their controlled release: A review. Applied Clay Science 2014, 88–89 (0), 239-269.
31. Rives, V. del Arco, M. Martín, C., Layered double hydroxides as drug carriers and for controlled release of non-steroidal antiinflammatory drugs (NSAIDs): A review. Journal of Controlled Release 2013, 169 (1–2), 28-39.
32. Liu, X. Gu, X. Zhang, S. Jiang, Y. Sun, J. Dong, M., Effects of dihydrogen phosphate intercalated layered double hydroxides on the crystal behaviors and flammability of polypropylene. Journal of Applied Polymer Science 2013, 130 (5), 3645-3651.
33. Yu, J. Chung, H.-E. Choi, S.-J., Acute Oral Toxicity and Kinetic Behaviors of Inorganic Layered Nanoparticles. Journal of Nanomaterials 2013, 2013, 8.
34. P. Newman, S. Jones, W., Synthesis, characterization and applications of layered double hydroxides containing organic guests. New Journal of Chemistry 1998, 22 (2), 105-115.
35. Shi, L. Li, D. Wang, J. Li, S. Evans, D. G. Duan, X., Synthesis, flame-retardant and smoke-suppressant properties of a borate-intercalated layered double hydroxide. Clays and Clay Minerals 2005, 53 (3), 294-300.
36. Walters, S. B. Hanna, B. A., Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterium growth indicator tube method. Journal of clinical microbiology 1996, 34 (6), 1565-7
37. Palaci, M. Ueki, S. Y. Sato, D. N. Da Silva Telles, M. A. Curcio, M. Silva, E. A., Evaluation of mycobacteria growth indicator tube for recovery and drug susceptibility testing of Mycobacterium tuberculosis isolates from respiratory specimens. Journal of clinical microbiology 1996, 34 (3), 762-4.
38. Chih-Chun Wen, H.-M. C., Swey-Shen Chen, Li-Ting Huang, Wei-Ting Chang, Wen-Chi Wei, Li-Chen Chou, Palanisamy Arulselvan, Jin-Bin Wu, Sheng-Chu Kuo and Ning-Sun Yang, Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines. Journal of biomedical science 2011, 18, 44.
39. Husain, A., Amide derivatives of sulfonamides and isoniazid: synthesis and biological evaluation. Acta Pol Pharm 2009, 66 (5), 513-21.
40. Akyuz, S. Akyuz, T., FT-IR and FT-Raman spectroscopic studies of adsorption of isoniazid by montmorillonite and saponite. Vibrational Spectroscopy 2008, 48 (2), 229-232.
41. DHAL .S. K., S. R., Development and Validation of RP-HPLC Method for Simultaneous Determination of Pyridoxine Hydrochloride, Isoniazid, Pyrazinamide and Rifampicin in pharmaceutical Formulation. Instytut Chemii Fizycznej: Warszawa, POLOGNE, 2009; Vol. 54, p 14.
42. Britto, S. Radha, A. V. Ravishankar, N. Kamath, P. V., Solution decomposition of the layered double hydroxide (LDH) of Zn with Al. Solid State Sciences 2007, 9 (3–4), 279-286.

43. Rojas, R. Palena, M. C. Jimenez-Kairuz, A. F. Manzo, R. H. Giacomelli, C. E., Modeling drug release from a layered double hydroxide–ibuprofen complex. *Applied Clay Science* 2012, 62–63 (0), 15-20.
44. Parello, M. L. Rojas, R. Giacomelli, C. E., Dissolution kinetics and mechanism of Mg–Al layered double hydroxides: A simple approach to describe drug release in acid media. *Journal of Colloid and Interface Science* 2010, 351 (1), 134-139.
45. Kong, X. Shi, S. Han, J. Zhu, F. Wei, M. Duan, X., Preparation of Glycyl-L-Tyrosine intercalated layered double hydroxide film and its in vitro release behavior. *Chemical Engineering Journal* 2010, 157 (2–3), 598-604.
46. Ho, Y. S. Ofomaja, A. E., Pseudo-second-order model for lead ion sorption from aqueous solutions onto palm kernel fiber. *Journal of hazardous materials* 2006, 129 (1-3), 137-42.
47. Kong, X. Jin, L. Wei, M. Duan, X., Antioxidant drugs intercalated into layered double hydroxide: Structure and in vitro release. *Applied Clay Science* 2010, 49 (3), 324-329.
48. Chen, X. T. Mi, F. Zhang, H. Zhang, H. Q., Facile synthesis of a novel magnetic core-shell hierarchical composite submicrospheres Fe₃O₄@CuNiAl-LDH under ambient conditions. *Mater Lett* 2012, 69, 48-51.

CHAPTER 9

CONCLUSION AND RECOMMENDATIONS

In this research different anti-tuberculosis (anti-TB) nanodelivery formulations were designed and synthesized by intercalation of anti-tuberculosis drugs namely para-aminosalicylic acid (second line anti-TB drug) and isoniazid (first line anti-TB drug) using the metal layered hydroxides (inorganic nanolayers) as hosts. Zinc layered hydroxides, zinc aluminium layered double hydroxides, and magnesium aluminium layered hydroxides were used as metal layered hydroxides host.

Para amino salicylic was successfully intercalated into zinc layered hydroxides using zinc oxide and zinc nitrate hexahydrate as precursors. Para amino salicylic acid was also intercalated into zinc aluminium layered double hydroxides by using coprecipitation and ion exchange methods.

Isoniazid was successfully intercalated into zinc aluminium layered double hydroxides applying coprecipitation and ion exchange methods. Isoniazid was also successfully intercalated into magnesium aluminium layered double hydroxides using ion exchange and coprecipitation methods.

The anti-TB drugs para-aminosalicylic acid and isoniazid from the metal layered hydroxides hosts (inorganic nanolayers) were found to be release in two stages manner initially fast followed by more stable slow release. However, the overall release of these drug was found to be sustained. The in vitro sustained release of the designed anti-TB nanodelivery formulations would enhance the bioavailability of these drugs in body for longer period of time.

Both of these drug are thermally stabilized by the metal layered hydroxides (inorganic nanolayers) due to the electrostatic interactions between the negatively charged drug and positively charged nanolayers. In addition the metal layered hydroxides would protect the drug from physico-chemical degradations inside the body and this would also result in the reduction in the adverse affects associated with these drugs.

The anti-mycobacterial and antimicrobial studies were conducted for the therapeutic comparative studies. The minimum inhibitory concentration (MIC) of free para amino salicylic acid (PAS) against mycobacteria tuberculosis was found to be 5.0 $\mu\text{g/mL}$. The effective MICs for the PAS-Zn/Al-LDHs (prepared by co precipitation method), PAS-Zn/Al-LDHs (prepared by ion exchange method), PAS-Zinc layered hydroxides (using ZnO precursor) and PAS-Zinc layered hydroxides (using zinc nitrated hexahydrated) were found to be 1.97 $\mu\text{g/mL}$, 1.98 $\mu\text{g/mL}$, 0.83 $\mu\text{g/mL}$, and 1.40 $\mu\text{g/mL}$ respectively against bacteria mycobacterium tuberculosis. The efficacy of PAS was improved 2.5 times by PAS-Zn/Al-LDHs (prepared by co precipitation method), PAS-Zn/Al-LDHs (prepared by ion exchange method). The efficacy of PAS was also found to be enhanced 5 times by PAS-Zinc layered hydroxides (using ZnO precursor) and it was increased 4 times by the PAS-Zinc layered hydroxides (using zinc nitrated hexahydrated).

Furthermore PAS based nanocomposites were also found active against Gram positive and Gram negative bacteria.

The MICs of the free drug, isoniazid against mycobacteria tuberculosis was found to be 2.3 $\mu\text{g}/\text{mL}$ and in comparison to this, effective MICs of isoniazid-Mg/Al-LDHs prepared by ion exchange and coprecipitation methods were found to be 0.37 μg and 0.44 μg ,

respectively. The therapeutic efficacy of isoniazid was enhanced about 5 times by its nanodelivery formulations with Mg/Al-LDHs compared to the free isoniazid.

The effective MICs of isoniazid zinc aluminium layered double hydroxides (INH-Zn/Al-LDHs) prepared by coprecipitation and ion exchange methods were found to be 0.91 μg and 0.62 μg against the mycobacteria tuberculosis. Comparison of MIC of free drug isoniazid with effective MICs of nanocomposites revealed that the therapeutic efficacy were enhanced by about 2.5 times and 3.7 time by isoniazid-Zn/Al-LDHs prepared by coprecipitation and ion exchange methods, respectively.

The enhanced efficacies of para amino salicylic acid and isoniazid in metal layered hydroxides intercalated forms can be attributed to the nanoscaled size, which helps the better internalization inside the mycobacteria tuberculosis and sustained release of these drugs for longer period of time.

The all of above mentioned nanocomposites-based para aminosalicic acid and isoniazid showed approximately four fold higher biocompatibility with human normal lung fibroblast cells MRC-5 and 3T3 fibroblast cells for up to 72 hours longer incubation period at the highest concentration of 50 $\mu\text{g}/\text{mL}$. Only exception to this was PAS-zinc layered hydroxides (prepared using ZnO precursor), which was found to show cytotoxicity in time concentration dependent manner with 3T3 fibroblast cells. However PAS-zinc layered hydroxides (prepared using ZnO precursor) was found to be highly biocompatible to human normal lung cells.

It can be concluded that metal layered hydroxides (inorganic nanolayers) fulfilled all the criteria of ideal drug delivery systems for anti-TB drugs and also for the other drugs due their high biocompatibility which would reduce the side effects, tendency to release the drugs in sustained manner, can protect the drugs from physico-chemical degradation, and enhances the therapeutic efficacy of the drugs.

The current research opens the horizon for the patient friendly tuberculosis treatment with high efficacy, low adverse affects and better therapeutic efficacy which would results in enhancement of patients; compliance to the chemotherapy of tuberculosis.

Table 9.1 Summary of the Research

Compounds	(%) Drug Loading	Sustained Release Period	(%) Viability of Human normal lung cells After 72 hours of incubation	MIC nanocomposites against bacteria M. tuberculosis	Effective MIC M.tuberculosis	Reference
Isoniazid (INH)	-	1-2 hours only	20	2.3 µg/mL	2.3 µg/mL	
INH-Mg/Al-LDHs (by coppt)	10.34%	3-5 days	86	3.60 µg/mL	0.37 µg/mL	Saifullah et al. 2014 (International Journal of nanomedicine)
INH-Mg/Al-LDHs (I.Exchange)	12.35	3-5 days	86	3.60 µg/mL	0.44 µg/mL	
INH-Zn/Al-LDHs (Co-ppt)	21.00	4-6 days	80	7.40 µg/mL	0.91 µg/mL	
INH-Zn/Al-LDHs (I. Exchange)	31.00	3-5 days	80	7.40 µg/mL	0.62 µg/mL	Saifullah et al. 2014 J.Nanobiotechnology (UR)
P. Salicylic acid (PAS)	---	1.5-2 hours	80	-	5.00 µg/mL	Saifullah et. 2013 Chemistry central. Journal
PAS-ZnLH LDHs (using ZnO)	17.00	1- 5 days	80	5.50 µg/mL	0.83 µg/mL	Saifullah et al. 2014 DDDT
PAS-ZnLH LDHs (using ZnZNO ₃)	22.40	0.5- 5 days	80	6.10 µg/mL	1.40 µg/mL	Saifullah et al. 2014 Scientific World J.
PAS-Zn/Al-LDHs (Coptt)	22.00	3- 5 days	80	7.90 µg/mL	1.73 µg/mL	Saifullah et al. 2013 DDDT
PAS-Zn/Al-LDHs (I.E)	16.60	3-5 days	80	12.40 µg/mL	2.00 µg/mL	Saifullah et al. 2014. DDDT

9.1 Selection of best nanodelivery system from the designed carriers

Almost all of the designed showed good drug delivery characteristics such as sustained release of the intercalated drugs, better therapeutic efficacy against the pathogenic bacteria mycobacteria tuberculosis and high biocompatibility with human normal lung cells. At this stage we cannot select best nanocomposite as all of them are found excellent nanodrug delivery systems in this *in vitro* research. Further *in vivo* studies for therapeutic efficacy on TB infected animal models and cytotoxicity studies on both healthy and infected animal are required for the selection the best delivery system among these designed drug delivery systems.

9.2 Recommendations

Further works should be carried out

- a) In designing the nanodelivery formulation-based on metal layered hydroxides (inorganic nanolayers) namely layered double hydroxides or layered hydroxy salts for different drugs, biomolecules, and genes etc., metal hydroxides such as magnesium hydroxides, zinc hydroxides and aluminium hydroxides can be used instead of using salts of these metal which contain competing anions.
- b) Use of metal hydroxides as precursors offer easy intercalation of neutral drugs molecules, even anionic drugs would easily be intercalated and further more final product would be free from contaminant, especially competing unwanted anions like nitrates, chlorides and acetate anions etc.
- c) *In vivo* studies of these developed anti-TB nanocomposites based on para amino salicylic acids, isoniazid and metal layered hydroxides should carried out for TB infected animals.
- d) *In vivo* anti-inflammatory studies using these nanocomposites should be carried out to investigate the affect on the animal tissues and organs.
- e) Pharmacokinetic studies can also be conducted using the developed anti-TB nanocomposites to determine extent of bioavailability of the drugs and to study the removal of degraded metal ions from the body.
- f) Nanocomposites prepared by using isoniazid as active agent should be tested against different cancer cell lines and isoniazid has been reported to possess anticancer activity.

BIODATA OF STUDENT

The student SAIFULLAH was born on 18th April 1982 in District Sukkur Sindh Pakistan. He received his primary education from the “Main primary school Sukkur”, secondary education from “Government High School Sukkur” Sindh Pakistan and Higher secondary studies from Govt: Comprehensive Higher Secondary School Sukkur Sindh Pakistan. His father late AHMED ALI BULLO was a high school teacher and retired as a High School principal. Mr. Saifullah has 10 siblings and he is number 7 out of 11. He did his Bachelor of Science (Hons) degree in chemistry and Master of Science degree in the field of Organic chemistry from Shah Abdul Latif University Khairpur, Sindh Pakistan in the year 2006. Then he joined International Centre for Chemical and Biological sciences (ICCBS) as a Research Officer and served there for five years till 2011. He was awarded fully funded Common wealth scholarship for Ph.D studies by Malaysian Higher Education Commission. In September 2011, he joined the Advanced Material and Nanotechnology Research group, Institute of Advanced Technology (ITMA) Universiti Putra Malaysia, under the supervision of Professor Dr. Mohd. Zobir Hussein. His area of research during his PhD was focussed on the nanosciences and nanomedicine. All of his research work has been published in the international journals.

LIST OF PUBLICATIONS

9.4.1 Research Publications

1. **Bullo Saifullah and** Mohd Zobir B Hussein . Inorganic nanolayers structure, preparation and biomedical application (Review article). International Journal of Nanomedicine-2014 (Accepted).
2. **Bullo Saifullah**, Palanisamy Arulselvan, Mohamed Ezzat El Zowalaty, Sharida Fakurazi, Thomas J Webster, Benjamin M Geilich, Mohd Zobir B Hussein. Development of biocompatible nanodelivery system for tuberculosis based on Isoniazid-Mg/Al Layered Double Hydroxide and its comparison with Isoniazid-Zn/Al- Layered Double Hydroxide. International Journal of Nanomedicine. 2014:9
3. **Bullo Saifullah**, Mohamed E.El Zowalaty, Palanisamy Arulselvan, Sharida Fakurazi, Thomas J Webster, Benjamin M Geilich, Mohd Zobir Hussein. Antimycobacterial, antimicrobial activities and biocompatibility of nanocomposites of Para aminosalicylic acid with ZnLH and Zn/Al LDHs. (Drug Design Development Therapy. Drug Design, Development and Therapy 2014:8 1029–1036.
4. **Bullo Saifullah**, Palanisamy Arulselvan, Mohamed Ezzat El Zowalaty, Sharida Fakurazi, Thomas J Webster, Benjamin M Geilich, Mohd Zobir B Hussein. Development of a highly biocompatible anti-tuberculosis nanodelivery formulation based on para-amino salicylic acid – zinc layered hydroxide nanocomposites. Scientific World Journal Volume 2014, Article ID 401460, 12 pages <http://dx.doi.org/10.1155/2014/401460>.
5. **Bullo Saifullah**, Mohd Zobir B Hussein, Samer Hassan Hussein al ali, Palanisamy Arulselvan. Sharida Fakurazi. Antituberculosis nanodelivery system with controlled-release properties based on para-aminosalicylate–zinc aluminum-layered double-hydroxide nanocomposites. Drug Design, Development and Therapy 2013:7
6. **Bullo Saifullah**, Mohd Zobir B Hussein, Samer Hassan Hussein al ali, Palanisamy Arulselvan. Sharida Fakurazi. Sustained release formulation of an anti-tuberculosis drug based on para-amino Salicylic acid-zinc layered hydroxide nanocomposite. Chemistry Central Journal 2013, 7:72
7. **Bullo Saifullah**, Mohd Zobir B Hussein, Samer Hussein al ali. Controlled-release approaches towards the chemotherapy of tuberculosis (Review article). International Journal of Nanomedicine 2012:7.5451-5463.
8. Samer Hasan Hussein Al Ali, Mothanna Al-Qubaisi, Mohd Zobir Hussein, Maznah Ismail, **Bullo Saifullah**. Hippuric acid nanocomposite enhances doxorubicin and oxaliplatin-induced cytotoxicity in MDA-MB231, MCF-7 and Caco2 cell lines. Drug Design, Development and Therapy 2013:7: 25-31.

9. **Bullo Saifullah and Mohd Zobir.** Advancement in biosensing technology by graphene-based biosensors. Journal of Biosensors & Bioelectronics 2014 (Under Review)
10. **Bullo Saifullah, Mohd Zobir B Hussein et al.** Biocompatible anti-tuberculosis nanodelivery formulation based on isoniazid-Zn/Al layered double of Nanobiotechnology 2014.
11. Aminu Umar Kura ,**Saifullah Bullo**, Pike-See Cheah Mohd Zobir Hussein, Norazrina Azmi, Sharida Fakurazi. Acute oral toxicity and biodistribution study of zinc aluminium-levodopa nanocomposite. Nanoscale Research letters (Springer)- (accepted- 2014).
12. **Bullo Saifullah**, Mohd Zobir Hussein, Tan Woan Sean, Palanisamy Arulselvan and Sharida Fakurazi. Drug delivery application of graphene oxide using para-aminosalicylic acid as model drug. Workshop on Advanced Materials and Nanotechnology 2014 (WAMN 2014), UPM, Malaysia, August 25-26, 2014.
13. Mohd Zobir Hussein, **Bullo Saifullah**, Tan Woan Sean, Palanisamy Arulselvan and Sharida Fakurazi. Graphene as a platform for an anti-tuberculosis nanodelivery system based on isoniazid. Advanced Material Conference 2014. Langkawi, Malaysia. 25-26 November 2014.
14. Mohd Zobir Hussein, **Bullo Saifullah**, Palanisamy Arulselvan, Mohamed Ezzat El Zowalaty, Sharida Fakurazi, Thomas J Webster, Benjamin M Geilich. Nanodelivery system for anti-tuberculosis drug based on Mg/Al and Zn/Al layered double hydroxides-isoniazid nanocomposites. The International Conference for Academic Disciplines 16-19 June 2014 at Casa Convalescencia, Sant Antoni Maria Claret 171, Barcelona, Spain.

Antimycobacterial, antimicrobial, and biocompatibility properties of para-aminosalicylic acid with zinc layered hydroxide and Zn/Al layered double hydroxide nanocomposites

Bullo Saifullah¹
 Mohamed E El Zowalaty^{2,3}
 Palanisamy Arulselvan²
 Sharida Fakurazi^{2,4}
 Thomas J Webster^{5,6}
 Benjamin M Geilich⁵
 Mohd Zobir Hussein¹

¹Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang, Selangor, Malaysia; ²Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; ³Department of Environmental Health, Faculty of Public Health and Tropical Medicine, Jazan University, Jazan, Saudi Arabia; ⁴Department of Human Anatomy, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; ⁵Department of Chemical Engineering and Program in Bioengineering, Northeastern University, Boston, MA, USA; ⁶Center of Excellence for Advanced Materials Research, King Abdulaziz University, Jeddah, Saudi Arabia

Correspondence: Mohd Zobir Hussein
 Materials Synthesis and Characterization
 Laboratory, Institute of Advanced
 Technology (ITMA), Universiti Putra
 Malaysia, 43400 Serdang, Selangor,
 Malaysia
 Tel +603 8946 6801
 Fax +603 8943 5380
 Email mzobir@upm.edu.my

This article was published in the following Dove Press journal:
 Drug Design, Development and Therapy
 28 July 2014
[Number of times this article has been viewed](#)

Abstract: The treatment of tuberculosis by chemotherapy is complicated due to multiple drug prescriptions, long treatment duration, and adverse side effects. We report here for the first time an in vitro therapeutic effect of nanocomposites based on para-aminosalicylic acid with zinc layered hydroxide (PAS-ZLH) and zinc-aluminum layered double hydroxides (PAS-Zn/Al LDH), against mycobacteria, Gram-positive bacteria, and Gram-negative bacteria. The nanocomposites demonstrated good antimycobacterial activity and were found to be effective in killing Gram-positive and Gram-negative bacteria. A biocompatibility study revealed good biocompatibility of the PAS-ZLH nanocomposites against normal human MRC-5 lung cells. The para-aminosalicylic acid loading was quantified with high-performance liquid chromatography analysis. In summary, the present preliminary in vitro studies are highly encouraging for further in vivo studies of PAS-ZLH and PAS-Zn/Al LDH nanocomposites to treat tuberculosis.

Keywords: Zn/Al-layered double hydroxides, zinc layered hydroxides, tuberculosis, para-aminosalicylic acid (PAS), antimicrobial agents

Introduction

Tuberculosis (TB) has been lethal to humans for centuries and despite significant technological advances, it still claims millions of precious human lives. According to a recent global TB report by the World Health Organization, about 8.6 million new cases of TB were reported with about 1.3 million deaths in 2013.¹

TB is a bacterial infectious disease caused by *Mycobacterium tuberculosis*, which generally targets the lungs (pulmonary TB) but can also infect other body organs like the liver, spleen, kidneys, tonsils, brains, intestine, etc, and is called extrapulmonary TB.² The aforementioned classification is based on the target site of the infection. However, TB can also be classified according to the treatment prescription, namely: 1) drug susceptible TB (DSTB) (the most common form of TB, which can be cured by the four first-line anti-TB drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol), 2) multidrug-resistant TB (MDR-TB) (the form of TB when bacteria become resistant to multiple anti-TB drugs, especially against isoniazid and rifampicin; MDR-TB is treated with second-line anti-TB drugs, namely para-aminosalicylic acid [PAS], cycloserine, aminoglycosides, fluoroquinolones, thioamides, and cyclopeptides),³ and 3) extensively resistant TB, where the bacteria become resistant to first-line anti-TB



Development of a biocompatible nanodelivery system for tuberculosis drugs based on isoniazid-Mg/Al layered double hydroxide

This article was published in the following Dove Press journal:
International Journal of Nanomedicine
9 October 2014
Number of times this article has been viewed

Bullo Saifullah¹
Palanisamy Arulselvan²
Mohamed Ezzat El
Zowalaty^{2,3}
Sharida Fakurazi^{2,4}
Thomas J Webster^{5,6}
Benjamin M Geilich⁵
Mohd Zobir Hussein¹

¹Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology,

²Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia;

³Department of Environmental Health, Faculty of Public Health and Tropical Medicine, Jazan University, Jazan, Saudi Arabia; ⁴Department of Human Anatomy, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia;

⁵Department of Chemical Engineering and Program in Bioengineering, Northeastern University, Boston, MA, USA; ⁶Center of Excellence for Advanced Materials Research, King Abdulaziz University, Jeddah, Saudi Arabia

Correspondence: Mohd Zobir Hussein
Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology, Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia
Tel +60 3 8946 6801
Fax +60 3 8943 5380
Email mzobir@upm.edu.my

Abstract: The primary challenge in finding a treatment for tuberculosis (TB) is patient non-compliance to treatment due to long treatment duration, high dosing frequency, and adverse effects of anti-TB drugs. This study reports on the development of a nanodelivery system that intercalates the anti-TB drug isoniazid into Mg/Al layered double hydroxides (LDHs). Isoniazid was found to be released in a sustained manner from the novel nanodelivery system in humans in simulated phosphate buffer solutions at pH 4.8 and pH 7.4. The nanodelivery formulation was highly biocompatible compared to free isoniazid against human normal lung and 3T3 mouse fibroblast cells. The formulation was active against *Mycobacterium tuberculosis* and gram-positive bacteria and gram-negative bacteria. Thus results show significant promise for the further study of these nanocomposites for the treatment of TB.

Keywords: tuberculosis, isoniazid, Mg/Al LDH, nanodelivery system

Introduction

Mycobacterium tuberculosis (MTB) causes pulmonary tuberculosis (TB) when the bacterium infects the lungs, and extrapulmonary TB where it infects other organs such as the kidneys, liver, spleen, intestine, tonsils, bones, and brain.¹ Patient non-compliance is the most common challenge in the treatment of TB; this is due to long treatment duration, adverse effects of anti-TB drugs, multidrug prescriptions, and frequent dosing.² TB has been a threat to human beings for centuries; the latest global TB report states that there were ~8.6 million people infected with TB and ~1.3 million died from the disease in 2012.³

Isoniazid (INH) is one of the most powerful anti-TB drugs among four first-line anti-TB drugs; namely rifampin, isoniazid, pyrazinamide, and ethambutol.⁴ Patients are required to take a 300 mg dose of isoniazid daily for 6 months in combination with other anti-TB agents.³ However, there are many undesirable side effects associated with isoniazid such as hepatotoxicity, jaundice, hyperacute liver failure, and hydralazine hypotension.⁴⁻⁷ Due to these adverse effects, the isoniazid dosage concentration is limited, and when the disease is treated with subtherapeutic doses, it can possibly develop resistance to that particular drug.⁸ Unfortunately, there have been no new anti-TB drugs introduced to the market over the past 5 decades.

Biocompatible drug delivery systems have been the focus of numerous studies since they can improve the efficacy of existing drugs.⁴ For example, drug delivery



Research Article

Development of a Highly Biocompatible Antituberculosis Nanodelivery Formulation Based on Para-Aminosalicylic Acid—Zinc Layered Hydroxide Nanocomposites

Bullo Saifullah,¹ Palanisamy Arulseivan,² Mohamed Ezzat El Zowalaty,^{2,3}
Sharida Fakurazi,^{2,4} Thomas J. Webster,^{5,6} Benjamin Geilich,⁵ and Mohd Zobir Hussein¹

¹ Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA),
Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia

² Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia,
43400 Serdang, Selangor, Malaysia

³ Department of Environmental Health, Faculty of Public Health and Tropical Medicine, Jazan University, Jazan, Saudi Arabia

⁴ Department of Human Anatomy, Faculty of Medicine and Health Science, Universiti Putra Malaysia,
43400 Serdang, Selangor, Malaysia

⁵ Department of Chemical Engineering and Program in Bioengineering, Northeastern University, Boston, MA 02115, USA

⁶ Center of Excellence for Advanced Materials Research, King Abdulaziz University, Jeddah 21589, Saudi Arabia

Correspondence should be addressed to Mohd Zobir Hussein; mzobir@upm.edu.my

Received 26 March 2014; Accepted 13 May 2014; Published 23 June 2014

Academic Editor: You Qiang

Copyright © 2014 Bullo Saifullah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tuberculosis is a lethal epidemic, difficult to control disease, claiming thousands of lives every year. We have developed a nanodelivery formulation based on para-aminosalicylic acid (PAS) and zinc layered hydroxide using zinc nitrate salt as a precursor. The developed formulation has a fourfold higher efficacy of PAS against mycobacterium tuberculosis with a minimum inhibitory concentration (MIC) found to be at 1.40 $\mu\text{g}/\text{mL}$ compared to the free drug PAS with a MIC of 5.0 $\mu\text{g}/\text{mL}$. The newly developed formulation was also found active against Gram-positive bacteria, Gram-negative bacteria, and *Candida albicans*. The formulation was also found to be biocompatible with human normal lung cells MRC-5 and mouse fibroblast cells-3T3. The *in vitro* release of PAS from the formulation was found to be sustained in a human body simulated phosphate buffer saline (PBS) solution at pH values of 7.4 and 4.8. Most importantly the nanocomposite prepared using zinc nitrate salt was advantageous in terms of yield and free from toxic zinc oxide contamination and had higher biocompatibility compared to one prepared using a zinc oxide precursor. In summary, these promising *in vitro* results are highly encouraging for the continued investigation of para-aminosalicylic acid and zinc layered hydroxide nano composites *in vivo* and eventual preclinical studies.

1. Introduction

Tuberculosis (TB) has remained lethal to humans for centuries and is of great public health concern. There were about 1.4 million human deaths from TB and about 8.7 million people infected in 2012 [1, 2]. TB is also the second greatest killer of humans in the world by a single infectious agent after HIV/AIDS [1]. The situation has become even more dire by the reemergence of multidrug resistant TB (MDR-TB) and in

2012, approximately 450,000 people developed MDR-TB and there was about 37% deaths of MDR-TB [1].

Chemotherapy of TB has been complicated by multidrug prescriptions, dosing frequency, longer treatment duration, and adverse side effects associated with anti-TB drugs [3, 4]. Since the drug development is lengthy, costly, and time consuming, it should not be surprising that no new anti-TB drug has reached the market in over 5 decades with the last anti-TB drug approved (rifampicin) in 1963 [3–5]. To cope

Controlled-release approaches towards the chemotherapy of tuberculosis

This article was published in the following Dove Press journal:
International Journal of Nanomedicine
11 October 2012
Number of times this article has been viewed

Bullo Saifullah¹
Mohd Zobir B Hussein^{1,2}
Samer Hasan Hussein Al Ali¹

¹Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; ²Advanced Materials and Nanotechnology Laboratory, Institute of Advanced Technology, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Abstract: Tuberculosis (TB), caused by the bacteria *Mycobacterium tuberculosis*, is notorious for its lethality to humans. Despite technological advances, the tubercle bacillus continues to threaten humans. According to the World Health Organization's 2011 global report on TB, 8.8 million cases of TB were reported in 2010, with a loss of 1.7 million human lives. As drug-susceptible TB requires long-term treatment of between 6 and 9 months, patient noncompliance remains the most important reason for treatment failure. For multidrug-resistant TB, patients must take second-line anti-TB drugs for 18–24 months and many adverse effects are associated with these drugs. Drug-delivery systems (DDSs) seem to be the most promising option for advancement in the treatment of TB. DDSs reduce the adverse effects of drugs and their dosing frequency as well as shorten the treatment period, and hence improve patient compliance. Further advantages of these systems are that they target the disease area, release the drugs in a sustained manner, and are biocompatible. In addition, targeted delivery systems may be useful in dealing with extensively drug-resistant TB because many side effects are associated with the drugs used to cure the disease. In this paper, we discuss the DDSs developed for the targeted and slow delivery of anti-TB drugs and their possible advantages and disadvantages.

Keywords: *Mycobacterium tuberculosis*, drug-delivery system, targeted delivery, anti-TB drug, TB, patient compliance

Introduction

Tuberculosis (TB), caused by the bacterium *Mycobacterium tuberculosis*, remains a most lethal disease in humans. The tubercle bacillus has tremendous ability to cope with the human immune system and has developed the ability to survive and do well within macrophage phagosomes. Despite technological advances, TB continues to threaten humans. According to the World Health Organization's 2011 global report on TB 2011 World Health Organization (WHO) report,¹ 8.8 million TB cases were reported in this year, approximately 1.35 million of which were fatal with an additional 0.35 million fatalities in individuals with HIV. TB remains among the three major causes of death among females aged 15–44 years old and approximately 320,000 women died due to TB in 2010. The identification and suitable treatment of multidrug-resistant TB (MDR-TB) remain the most important aspects to be addressed. Furthermore, TB's resistance to contemporary TB antibiotics is due to its dormant form in the host cells. It is known that rifampin, isoniazid, and ethambutol (but not pyrazinamide) require bacteria to reproduce in order to perform their function. It is thought that the bacteria's ability to remain dormant allows them to be phenotypically resistant to prescribed antibiotics.^{2,3}

Correspondence: Mohd Zobir B Hussein
Department of Chemistry, Faculty of Science, Universiti Putra Malaysia,
43400 UPM, Serdang, Selangor, Malaysia
Tel +603 8946 6801
Fax +603 8943 5380
Email mzobir@science.upm.edu.my

RESEARCH ARTICLE

Open Access

Sustained release formulation of an anti-tuberculosis drug based on para-amino salicylic acid-zinc layered hydroxide nanocomposite

Bullo Saifullah¹, Mohd Zobir Hussein^{1*}, Samer Hasan Hussein-Al-Alli², Palanisamy Arulselvan³ and Sharida Fakurazi^{3,4}

Abstract

Background: Tuberculosis (TB), is caused by the bacteria, *Mycobacterium tuberculosis* and its a threat to humans since centuries. Depending on the type of TB, its treatment can last for 6–24 months which is a major cause for patients non compliance and treatment failure. Many adverse effects are associated with the currently available TB medicines, and there has been no new anti tuberculosis drug on the market for more than 50 year, as the drug development is very lengthy and budget consuming process.

Development of the biocompatible nano drug delivery systems with the ability to minimize the side effects of the drugs, protection of the drug from enzymatic degradation. And most importantly the drug delivery systems which can deliver the drug at target site would increase the therapeutic efficacy. Nanovehicles with their tendency to release the drug in a sustained manner would result in the bioavailability of the drugs in the body for a longer period of time and this would reduce the dosing frequency in drug administration. The biocompatible nanovehicles with the properties like sustained release of drug of the target site, protection of the drug from physico chemical degradation, reduction in dosing frequency, and prolong bioavailability of drug in the body would result in the shortening of the treatment duration. All of these factors would improve the patient compliance with chemotherapy of TB.

Result: An anti tuberculosis drug, 4 amino salicylic acid (4 ASA) was successfully intercalated into the interlamellae of zinc layered hydroxide (ZLH) via direct reaction with zinc oxide suspension. The X ray diffraction patterns and FTIR analyses indicate that the molecule was successfully intercalated into the ZLH interlayer space with an average basal spacing of 24 Å. Furthermore, TGA and DTG results show that the drug 4 ASA is stabilized in the interlayers by electrostatic interaction. The release of 4 ASA from the nanocomposite was found to be in a sustained manner. The nanocomposite treated with normal 3T3 cells shows it reduces cell viability in a dose and time dependent manner.

Conclusions: Sustained release formulation of the nanocomposite, 4 ASA intercalated into zinc layered hydroxides, with its ease of preparation, sustained release of the active and less toxic to the cell is a step forward for a more patient friendly chemotherapy of Tuberculosis.

Keywords: Para Amino salicylic acid (PAS/4 ASA), MDR TB, Zinc layered hydroxide, Nanocomposite, 3T3 cell lines

* Correspondence: mzobir@putra.upm.edu.my

¹Materials Synthesis and Characterization Laboratory (MSCL), Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia

Full list of author information is available at the end of the article



Antituberculosis nanodelivery system with controlled-release properties based on para-amino salicylate–zinc aluminum-layered double-hydroxide nanocomposites

This article was published in the following Dove Press journal:
Drug Design, Development and Therapy
12 November 2013
Number of times this article has been viewed

Bullo Saifullah¹
Mohd Zobir Hussein¹
Samer Hasan Hussein-Al-Ali²
Palanisamy Arulselvan³
Sharida Fakurazj^{3,4}

¹Materials Synthesis and Characterization Laboratory,
²Laboratory of Molecular Biomedicine,
³Laboratory of Vaccines and Immunotherapeutics, ⁴Department of Human Anatomy, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Abstract: We report the intercalation and characterization of para-amino salicylic acid (PASA) into zinc/aluminum-layered double hydroxides (ZLDHs) by two methods, direct and indirect, to form nanocomposites: PASA nanocomposite prepared by a direct method (PASA-D) and PASA nanocomposite prepared by an indirect method (PASA-I). Powder X-ray diffraction, Fourier-transform infrared spectroscopy, and thermogravimetric analysis revealed that the PASA drugs were accommodated within the ZLDH interlayers. The anions of the drug were accommodated as an alternate monolayer (along the long-axis orientation) between ZLDH interlayers. Drug loading was estimated to be 22.8% and 16.6% for PASA-D and PASA-I, respectively. The in vitro release properties of the drug were investigated in physiological simulated phosphate-buffered saline solution of pH 7.4 and 4.8. The release followed the pseudo-second-order model for both nanocomposites. Cell viability (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide [MTT] assays) was assessed against normal human lung fibroblast MRC-5 and 3T3 mouse fibroblast cells at 24, 48, and 72 hours. The results showed that the nanocomposite formulations did not possess any cytotoxicity, at least up to 72 hours.

Keywords: drug-delivery system, slow-release nanocarrier, tuberculosis, biocompatible nanocomposites

Introduction


Layered double hydroxides (LDHs) have a hydrotalcite-like structure in which some of the divalent cations are replaced by trivalent cations, which results in positively charged brucite-like sheets stacked on top of one another, resulting in a layered structure. The positive charge of these brucite-like nanosheets is neutralized by the anions and water molecules.¹ A variety of anions can be accommodated between the layers to counter balance the positive charge and this tendency makes them versatile to be used for different applications. The anions can be inorganic, like halides, nitrates, and sulfates, and organic, like drugs, amino acids, dyes, polymers, and DNA etc.^{1,2} LDHs are represented by the general formula $(M^{II}_{1-x}M^{III}_x[OH]_2)(A_{x/n}^{n-}) \cdot yH_2O$, in which M^{II} is a divalent metal ion, M^{III} is a trivalent metal ion, and anions are used to neutralize the positive charge of the sheets. The LDHs have many applications, such as their use for extraction of toxic waste from water,³ in catalysis,⁴ and as a flame retardant,⁵ and they have also been used in chiral separation.⁶ Recently, the most important application of LDHs has been investigated, particularly slow-release drug-delivery systems. Different drugs have been intercalated recently into nanosheets of LDHs, such as anticancer drugs, antihistamines, antidiabetics, and antimicrobials.^{7,8}

Correspondence: Mohd Zobir Hussein
Materials Synthesis and Characterization
Laboratory (MSCL), Institute of Advanced
Technology (ITMA), Universiti Putra
Malaysia, Serdang, Selangor 43400,
Malaysia
Tel +60 3 8946 6801
Fax +60 3 8943 5380
Email mzobir@putra.upm.edu.my

submit your manuscript | www.dovepress.com
Dovepress
<http://dx.doi.org/10.2147/DDT.S58645>

Drug Design, Development and Therapy 2013:7 | 1365–1375

1365

 © 2013 Saifullah et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at <http://creativecommons.org/licenses/by-nc/3.0/>. Non-commercial use of the work is permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at <http://www.dovepress.com/permissions.php>

9.4.2 Conferences /Workshops/ Posters/ Proceedings

1. **Bullo Saifullah**, Mohd Zobir Hussein . Drug delivery application of graphene oxide using para-aminosalicylic acid as model drug. Workshop on Advanced Materials and Nanotechnology 2014 (WAMN 2014), UPM, Malaysia, August 25-26, 2014.
2. **Mohd Zobir Hussein***, **Bullo Saifullah et al.** Graphene as a platform for an anti-tuberculosis nanodelivery system based on isoniazid. Advanced Material Conference 2014. Langkawi, Malaysia. 25-26 November 2014.
3. **Mohd Zobir Hussein, Bullo Saifullah et al.** Nanodelivery system for anti-tuberculosis drug based on Mg/Al and Zn/Al layered double hydroxides-isoniazid nanocomposites The International Conference for Academic Disciplines 16-19 June 2014 at Casa Convalescencia, Sant Antoni Maria Claret 171, Barcelona, Spain.
4. **The 6th Nanotechnology cancer Asia-pacific (NCAP) Network Meeting** (Healthcare Session I of APAN 37th Video Conferencing meeting) IDEC Alpha University Putra Malaysia 23 January 2014.
5. **Workshop on Advanced Materials and Nanotechnology 2013 (WAMN)**, Organized by Institute of Advanced Technology (ITMA), University Putra Malaysia (UPM), 10-11 September 2013
6. **Nanomaterials and Nanodelivery Workshop 2013.** Organized by Laboratory of Molecular Medicine, Institute of Bioscience, University Putra Malaysia 25th April
7. **43rd Union World Conference on Lung Health 2012.** Held in Kuala Lumpur from 13-17 November 2012, organized by the International Union Against Tuberculosis and Lung Disease (The Union).
8. **Animal Cell Culture Workshop 25-27th June 2012.** Organized by Laboratory of Vaccines and Immunotherapeutics Institute of Bioscience (IBS), University Putra Malaysia (UPM).
9. **Workshop on Advanced Materials and Nanotechnology 2011 (WAMN2011).** Organized by Institute of Advanced Technology (ITMA), Faculty of engineering & Faculty of Science UPM, 16-17th November 2011.



UNIVERSITI PUTRA MALAYSIA

STATUS CONFIRMATION FOR THESIS / PROJECT REPORT AND COPYRIGHT

ACADEMIC SESSION : FIRST SEMESTER 2014/2015

TITLE OF THESIS / PROJECT REPORT :

DEVELOPMENT OF NANODELIVERY SYSTEMS FOR ANTI-TUBERCULOSIS DRUGS USING METAL HYDROXIDES NANOLAYERED HOSTS.

NAME OF STUDENT : SAIFULLAH

I acknowledge that the copyright and other intellectual property in the thesis/project report belonged to Universiti Putra Malaysia and I agree to allow this thesis/project report to be placed at the library under the following terms:

1. This thesis/project report is the property of Universiti Putra Malaysia.
2. The library of Universiti Putra Malaysia has the right to make copies for educational purposes only.
3. The library of Universiti Putra Malaysia is allowed to make copies of this thesis for academic exchange.

I declare that this thesis is classified as :

*Please tick (v)

CONFIDENTIAL

(Contain confidential information under Official Secret Act 1972).

RESTRICTED

(Contains restricted information as specified by the organization/institution where research was done).

OPEN ACCESS

I agree that my thesis/project report to be published as hard copy or online open access.

This thesis is submitted for :

PATENT

(part of possibility it is possible)

Embargo from 19/Nov/2014 until 18/Nov/2015
(date) (date)

Sai (BM3797772)

(Signature of Student)
New IC No/ Passport No.:

Date : 19-11-2014

Approved by:

PROF DR MOHD ZOBIR HUSSEIN

MATERIALS SYNTHESIS AND CHARACTERISATION LABORATORY (MSCL)
INSTITUTE OF ADVANCED TECHNOLOGY (ITMA)

(Signature of Chairman of Supervisory Committee)
Name:

Date : 19 Nov 2014

[Note : If the thesis is CONFIDENTIAL or RESTRICTED, please attach with the letter from the organization/institution with period and reasons for confidentiality or restricted.]